Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. JAZZ
stocks logo

JAZZ

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.16B
+6.46%
6.136
-7.03%
987.06M
+9.94%
5.205
+209.82%
1.10B
+5.49%
5.965
-172.3%
Estimates Revision
The market is revising Upward the revenue expectations for Jazz Pharmaceuticals plc (JAZZ) for FY2025, with the revenue forecasts being adjusted by 0.14% over the past three months. During the same period, the stock price has changed by 20.63%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.14%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.02%
In Past 3 Month
Stock Price
Go Up
up Image
+20.63%
In Past 3 Month
Wall Street analysts forecast JAZZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAZZ is 193.55 USD with a low forecast of 147.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast JAZZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAZZ is 193.55 USD with a low forecast of 147.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 136.710
sliders
Low
147.00
Averages
193.55
High
230.00
Current: 136.710
sliders
Low
147.00
Averages
193.55
High
230.00
JPMorgan
Overweight
downgrade
$204 -> $199
2025-10-27
Reason
JPMorgan
Price Target
$204 -> $199
2025-10-27
downgrade
Overweight
Reason
JPMorgan lowered the firm's price target on Jazz Pharmaceuticals to $199 from $204 and keeps an Overweight rating on the shares. The firm updated the company's model ahead of the Q3 report.
Morgan Stanley
NULL
to
Overweight
upgrade
$167 -> $180
2025-10-20
Reason
Morgan Stanley
Price Target
$167 -> $180
2025-10-20
upgrade
NULL
to
Overweight
Reason
Morgan Stanley raised the firm's price target on Jazz Pharmaceuticals to $180 from $167 and keeps an Overweight rating on the shares. The firm has updated its model for the quarter and adjusted its operating expense view, noting that Jazz is expected to announce its Q3 earnings call in early November.
Morgan Stanley
analyst
Overweight
maintain
$163 -> $167
2025-09-24
Reason
Morgan Stanley
analyst
Price Target
$163 -> $167
2025-09-24
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Jazz Pharmaceuticals to $167 from $163 and keeps an Overweight rating on the shares after the company presented data from the Xywav Phase 4 DUET study evaluating low-sodium oxybate at World Sleep Singapore. The data show that oxybates are differentiated and can directly improve sleep architecture, says the analyst, who increased the firm's Xywav market share estimates in FY28-33.
Morgan Stanley
maintain
$162 -> $163
2025-08-28
Reason
Morgan Stanley
Price Target
$162 -> $163
2025-08-28
maintain
Reason
Morgan Stanley raised the firm's price target on Jazz Pharmaceuticals to $163 from $162 and keeps an Overweight rating on the shares. Given disease severity and potential for accelerated uptake in academic centers, the firm raised its Modeyso peak second-line market share estimate to 43% from 22%, sending its peak Modeyso sales estimate up to $389M from $271M and driving its price target up by $1, the analyst tells investors.
BofA
Jason Gerberry
Buy
maintain
$217 -> $230
2025-08-14
Reason
BofA
Jason Gerberry
Price Target
$217 -> $230
2025-08-14
maintain
Buy
Reason
BofA analyst Jason Gerberry raised the firm's price target on Jazz Pharmaceuticals to $230 from $217 and keeps a Buy rating on the shares. Following the recent approval of Modeyso for treatment of an ultra-rare brain tumor, the firm spoke with two key opinion leaders, who offered "positive feedback" on Modeyso uptake and the odds of success for the confirmatory Phase 3 study, the analyst tells investors. While Modeyso's lead U.S. indication for the recurrent setting is likely to be niche, the firm came away from the expert calls "more assured" about the prospects for the confirmatory ACTION trial, which could boost peak U.S. sales to greater than $400M, the analyst added.
BofA
Buy
maintain
$217 -> $225
2025-08-14
Reason
BofA
Price Target
$217 -> $225
2025-08-14
maintain
Buy
Reason
BofA raised the firm's price target on Jazz Pharmaceuticals to $225 from $217 and keeps a Buy rating on the shares. Following the recent approval of Modeyso for treatment of an ultra-rare brain tumor, the firm spoke with two key opinion leaders, who offered "positive feedback" on Modeyso uptake and the odds of success for the confirmatory Phase 3 study, the analyst tells investors. While Modeyso's lead U.S. indication for the recurrent setting is likely to be niche, the firm came away from the expert calls "more assured" about the prospects for the confirmatory ACTION trial, which could boost peak U.S. sales to greater than $400M, the analyst added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Jazz Pharmaceuticals PLC (JAZZ.O) is 5.71, compared to its 5-year average forward P/E of 8.03. For a more detailed relative valuation and DCF analysis to assess Jazz Pharmaceuticals PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
8.03
Current PE
5.71
Overvalued PE
10.39
Undervalued PE
5.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
7.55
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8.92
Undervalued EV/EBITDA
6.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.53
Current PS
137.11
Overvalued PS
16.69
Undervalued PS
-9.62
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

JAZZ News & Events

Events Timeline

(ET)
2025-11-05
16:14:55
Jazz Pharmaceuticals increases FY25 adjusted EPS forecast to $7.65-$8.45, up from $4.80-$5.60
select
2025-11-05
16:12:41
Jazz Pharmaceuticals announces Q3 adjusted EPS of $8.13, surpassing consensus of $5.85
select
2025-10-22 (ET)
2025-10-22
06:33:28
Avadel reveals worldwide resolution of all legal disputes with Jazz Pharmaceuticals.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-11Newsfilter
PinnedJazz Pharmaceuticals Presents Latest Clinical and Translational Findings for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025

  • Jazz Pharmaceuticals' Research Progress: Jazz Pharmaceuticals is set to present five abstracts at the 2025 Society for Neuro-Oncology Annual Meeting, showcasing advancements in brain tumor research, particularly focusing on Modeyso™ (dordaviprone) and JZP3507 in treating aggressive CNS tumors.

  • Modeyso™ Approval and Mechanism: Modeyso, approved by the FDA for H3 K27M-mutant diffuse midline glioma, is a mitochondrial caseinolytic protease P (ClpP) agonist that influences tumor metabolism and immune response, offering new hope for patients with limited treatment options.

[object Object]
Preview
9.0
11-11NASDAQ.COM
PinnedJazz Pharma to Showcase Modeyso Data at the Annual Society for Neuro-Oncology Meeting

  • Upcoming Presentation: Jazz Pharmaceuticals will present new clinical and translational data for Modeyso at the 2025 Society for Neuro-Oncology Annual Meeting in Honolulu from November 19-23.

  • FDA Approval: Modeyso is the first FDA-approved treatment for H3 K27M-mutant diffuse midline glioma, a rare and aggressive brain tumor affecting about 2,000 people in the U.S. annually.

  • Research Focus: The presentations will include both clinical and preclinical research on Modeyso, as well as new data on JZP3507 for central nervous system tumors.

  • Stock Performance: Jazz Pharmaceuticals' stock has fluctuated between $95.49 and $148.06 over the past year, closing at $133.19, a 1.55% increase from the previous day.

[object Object]
Preview
9.5
11-06NASDAQ.COM
Jazz Pharmaceuticals Plc Reports Improvement in Q3 Earnings

  • Earnings Report: Jazz Pharmaceuticals plc reported a third-quarter earnings increase, with a net income of $251.4 million, or $4.08 per share, compared to $215.1 million, or $3.42 per share, from the previous year.

  • Adjusted Earnings: The company’s adjusted earnings for the quarter were $500.7 million, or $8.13 per share, reflecting strong performance excluding certain items.

  • Revenue Growth: Revenue for the period rose by 6.8% to $1.126 billion, up from $1.054 billion in the same quarter last year.

  • Future Guidance: Jazz Pharmaceuticals provided full-year EPS guidance of $7.65 to $8.45 and revenue guidance of $4.175 billion to $4.275 billion.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Jazz Pharmaceuticals PLC (JAZZ) stock price today?

The current price of JAZZ is 136.71 USD — it has decreased -0.29 % in the last trading day.

arrow icon

What is Jazz Pharmaceuticals PLC (JAZZ)'s business?

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

arrow icon

What is the price predicton of JAZZ Stock?

Wall Street analysts forecast JAZZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAZZ is 193.55 USD with a low forecast of 147.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Jazz Pharmaceuticals PLC (JAZZ)'s revenue for the last quarter?

Jazz Pharmaceuticals PLC revenue for the last quarter amounts to 1.13B USD, increased 6.74 % YoY.

arrow icon

What is Jazz Pharmaceuticals PLC (JAZZ)'s earnings per share (EPS) for the last quarter?

Jazz Pharmaceuticals PLC. EPS for the last quarter amounts to 4.08 USD, increased 19.30 % YoY.

arrow icon

What changes have occurred in the market's expectations for Jazz Pharmaceuticals PLC (JAZZ)'s fundamentals?

The market is revising Upward the revenue expectations for Jazz Pharmaceuticals plc (JAZZ) for FY2025, with the revenue forecasts being adjusted by 0.14% over the past three months. During the same period, the stock price has changed by 20.63%.
arrow icon

How many employees does Jazz Pharmaceuticals PLC (JAZZ). have?

Jazz Pharmaceuticals PLC (JAZZ) has 2800 emplpoyees as of November 13 2025.

arrow icon

What is Jazz Pharmaceuticals PLC (JAZZ) market cap?

Today JAZZ has the market capitalization of 8.31B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free